SMSPHARMA Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹238 Cr
verified against source
Revenue YoY
13%
reported change
EBITDA
₹171 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
SMS Pharmaceuticals delivered solid FY26 results with 13% revenue growth to Rs 887 crore and 23% EBITDA growth to Rs 171 crore, with margins expanding to 20%. Q4 standalone PAT of Rs 21 crore (including Rs 12 crore from associate BKD Pharma) beat year-ago levels. The EBITDA margin improvement reflects benefits from backward integration, favorable product mix, and operating leverage. Gross margin contracted quarter-on-quarter due to rising solvent costs from Middle East geopolitical tensions. Management guides conservatively for 15% revenue growth in FY27 while targeting 22%+ EBITDA margins, with upside potential to 20-25% growth if external conditions stabilize. The 280 crore brownfield expansion (130 crore already invested) to increase capacity to 800 MT/month remains on track for FY27 completion with revenue impact from FY28. Key risks include customer concentration (28% from top customer), export-heavy business (70% currently, moving to 75%), and geopolitical supply chain volatility affecting raw material costs. Peptides and CMO initiatives remain medium-term opportunities with clarity expected in 2 quarters.
Colored figures show movement against the previous available record.
Guidance to track
- Conservative guidance of 15% revenue growth for FY27 accounts for ongoing geopolitical uncertainties affecting logistics and supply chain stability. Upside potential exists if external environment stabilizes.
- Management targets 22% EBITDA margin in FY27, up from 20% in FY26, driven by backward integration benefits and improved operating leverage. This would exceed the historical all-time high of 22%.
- Beyond FY27, management's actual target is 20-25% growth rate, with conservatism in near-term guidance due to geopolitical risks. New API launches and capacity expansion expected to drive acceleration from FY28.
- Brownfield expansion with 4-5 new high-value, high-margin APIs expected to begin meaningful contribution in FY28 with further scale-up in FY29. Peptide platform and CDMO initiatives also targeting FY29 contributions.
Risks flagged
- Middle East tensions causing sharp increases in solvent costs, which impacted Q4 gross margins on quarter-on-quarter basis. This external factor remains outside management control and could continue to pressure margins if conflict persists.
- Single largest customer group accounts for 28% of total revenue across multiple products. Management declined to identify the customer. Concentration risk remains significant if this relationship weakens.
- Existing capacity at 80% utilization while expansion is underway creates operational tightness. Any delays in the FY27 brownfield completion could impact volume growth and customer commitments already made for the year.
- 70% of revenue currently from exports, expected to rise to 75% with new API launches. Currency volatility and geopolitical logistics disruptions create dual exposure to export revenue and raw material imports.
Key quotes
- FY27 was a year of rebuilding the foundation for the next phase of growth. Over the last 3 years, we have invested significantly in backward integration, product registrations, plant engineering, and capacity expansion. Much of this work requires time before it translates to commercial results.
- The main important driver will be the backward integration because for a very key important product like ibuprofen if we've not backward integrated like we've not taken the skull of backward integration a couple of years back we would have probably been in a very bad situation now because of the current market scenarios.
- Our all-time high EBITDA margin was around 22% and definitely we are targeting that this year and in subsequent years we're trying to probably exceed that.
Research modules